CFM
NKTR icon

Catalyst Funds Management’s Nektar Therapeutics NKTR Stock Holding History

Catalyst Funds Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,700
Closed -$482K – 806
2026
Q1 		$482K Buy
+6,700
New +$381K 0.08% 253

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's NKTR Position: Q2 2026 in Review

Catalyst Funds Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 6,700 shares — an estimated $482K sold.

Catalyst Funds Management first reported a position in NKTR in Q1 2026 and held it in 1 quarter. The position peaked at $482K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Catalyst Funds Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 6,700 Nektar Therapeutics shares in Q2 2026, an estimated $482K.
  • Catalyst Funds Management first reported a position in Nektar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Nektar Therapeutics position peaked at $482K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.